Management of Metastatic Head and Neck Squamous Cell Carcinoma
For first-line treatment of metastatic HNSCC, pembrolizumab combined with platinum and 5-fluorouracil is the preferred regimen for most patients, offering superior progression-free and overall survival compared to other options. 1
Treatment Algorithm Based on PD-L1 Status
The 2023 ASCO guidelines provide a clear algorithmic approach based on PD-L1 combined positive score (CPS) testing 1:
For PD-L1 CPS ≥ 1 (Positive):
- First choice: Pembrolizumab + platinum + 5-FU
- Alternative: Pembrolizumab monotherapy (acceptable but less effective)
For PD-L1 CPS < 1:
- Recommended: Pembrolizumab + platinum + 5-FU (still recommended despite negative PD-L1)
For Platinum-Refractory Disease (Any PD-L1 Status):
- Recommended: Nivolumab monotherapy
When PD-L1 Testing Unavailable:
- Consider TMB (tumor mutational burden) testing
- If TMB ≥ 10: Interpret as high and correlating with clinical benefit to PD-1 inhibitors 1
Real-World Performance Data
Recent multicenter real-world data from 290 patients demonstrates the superiority of combination therapy 2:
- Pembrolizumab + chemotherapy: Median PFS 6 months, OS 15.5 months
- Pembrolizumab monotherapy: Median PFS 2.9 months, OS 9.4 months
- TPExtreme regimen: Median PFS 5.9 months, OS 13.7 months
This real-world evidence strongly supports pembrolizumab-chemotherapy combination as the preferred first-line option, particularly for patients who can tolerate chemotherapy.
Special Populations
Nasopharyngeal Cancer:
- First-line: Toripalimab, camrelizumab, or tislelizumab with gemcitabine and cisplatin
- If unavailable: Pembrolizumab or nivolumab with gemcitabine and cisplatin 1
Oligometastatic Disease:
- Consider local therapy (radiation or surgery) for curative intent 3
- Radiation therapy is safe to give concurrently with immunotherapy for palliation or local control
- Critical caveat: Do not use radiation to enhance immunotherapy response outside clinical trials 1
Rare Head and Neck Cancers (e.g., Salivary Gland):
- TMB testing becomes more important
- If TMB-high: PD-1 inhibitors are appropriate 1
Key Decision Points
When to choose pembrolizumab monotherapy over combination therapy:
- Patients with excellent PD-L1 expression (CPS ≥ 20) who prioritize quality of life over maximal disease control
- Patients unfit for chemotherapy due to comorbidities, poor performance status, or nutritional compromise
- Patient preference after informed discussion of trade-offs 4
Important caveat: Pembrolizumab monotherapy has significantly inferior PFS (2.9 vs 6 months) and OS (9.4 vs 15.5 months) compared to combination therapy 2. This difference is clinically meaningful in rapidly progressive disease at high-risk anatomic locations.
Safety Profile Considerations
The 2025 real-world study confirms that pembrolizumab monotherapy is the safest regimen with fewer grade 3-4 adverse events 2. However, this safety advantage must be weighed against substantially inferior efficacy outcomes.
Combination pembrolizumab-chemotherapy carries typical platinum-based chemotherapy toxicities (nephrotoxicity, myelosuppression, nausea) but provides the best chance for disease control and survival prolongation 1, 2.
Common Pitfalls to Avoid
Do not withhold pembrolizumab-chemotherapy combination solely based on PD-L1 CPS < 1 - the guidelines still recommend combination therapy in this population 1
Do not delay PD-L1 testing - this is essential for treatment planning and should be performed on all recurrent/metastatic HNSCC specimens 1, 5
Do not use radiation therapy to boost immunotherapy response outside clinical trials - while safe for palliation, there is no evidence supporting this approach for response enhancement 1
Do not assume all patients need combination therapy - carefully selected patients with excellent PD-L1 expression and strong preference for quality of life may benefit from monotherapy 4
The 2019 SITC consensus and 2023 ASCO guidelines both emphasize that these immunotherapy-based regimens represent the first major therapeutic advances since 2006 1, 5, fundamentally changing the treatment paradigm for metastatic HNSCC from purely palliative to potentially disease-modifying therapy.